PHN031

PHN031 is an investigational small‑molecule osteogenesis stimulant being developed by PhytoHealth for the treatment of osteoporosis. It is positioned as a bone‑forming agent intended to enhance bone formation and improve bone mineral density in patients with osteoporosis, including postmenopausal osteoporosis. PHN031 has undergone Phase II clinical trials under a US FDA IND for osteoporosis, including studies conducted in Taiwan, but detailed target, molecular structure, and pharmacology have not been publicly disclosed. The program is a part of PhytoHealth’s broader botanical and small‑molecule pipeline focused on chronic metabolic and musculoskeletal diseases.